Ovid Therapeutics Inc

NASDAQ:OVID   3:38:07 PM EDT
1.77
-0.03 (-1.67%)
Earnings Announcements

Ovid Therapeutics Reports Q3 Financial Results, Corporate Highlights

Published: 11/08/2022 14:04 GMT
Ovid Therapeutics Inc (OVID) - Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights.
Qtrly Loss per Share $0.17.
Q3 Loss per Share $0.17.
Ended Quarter With Cash, Cash Equivalents, Marketable Securities $137.9 Million.
Quarter End Cash, Cash Equivalents, Marketable Securities Expected to Support Advancement of Ovid's Epilepsy Pipeline Into 2025.
Q3 Earnings per Share View $-0.21 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.18

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.19

More details on our Analysts Page.